Accelerate Stock Analysis

AXDX -  USA Stock  

USD 8.61  0.07  0.82%

The small slide in market price for the last few months could raise concerns from investors as the firm it trading at a share price of 8.61 on 39,263 in volume. The company executives did not add much value to Accelerate Diagnosti investors in May. However, diversifying your holdings with Accelerate Diagnosti or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 2.97. The current volatility is consistent with the ongoing market swings in May 2021 as well as with Accelerate Diagnosti unsystematic, company-specific events.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Accelerate Diagnosti stock analysis report makes it easy to digest most publicly released information about Accelerate Diagnosti and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Accelerate stock analysis module also helps to analyze the Accelerate Diagnosti price relationship with some important fundamental indicators such as market cap and management efficiency.

Accelerate Stock Analysis Notes

About 44.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.4. Accelerate Diagnosti had not issued any dividends in recent years. The entity had 1:4 split on the 19th of November 1996. Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 224 people. For more info on Accelerate Diagnosti please contact Lawrence Mehren at 520 365-3100 or go to www.acceleratediagnostics.com.

Accelerate Diagnosti Quarterly Cost of Revenue

1.62 MillionShare

Accelerate Diagnosti Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Accelerate Diagnosti's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Accelerate Diagnosti or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Accelerate Diagnosti generates negative expected return over the last 90 days
Accelerate Diagnosti has a very high chance of going through financial distress in the upcoming years
Accelerate Diagnosti was previously known as Accelerate Diagnostics and was traded on NASDAQ Exchange under the symbol AXK.
The company reported the previous year's revenue of 11.16 M. Net Loss for the year was (78.21 M) with profit before overhead, payroll, taxes, and interest of 4.46 M.
Accelerate Diagnosti currently holds about 68.27 M in cash with (50.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15.
Roughly 44.0% of the company shares are held by company insiders
Latest headline from health.economictimes.indiatimes.com: AMR -- The insidious and silent pandemic in making - ETHealthworld.com

Accelerate Diagnosti Upcoming and Recent Events

Earnings reports are used by Accelerate Diagnosti to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Accelerate Diagnosti previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Accelerate Largest EPS Surprises

Earnings surprises can significantly impact Accelerate Diagnosti's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
1998-11-16
1998-09-30-0.02-0.04-0.02100 
1998-05-20
1998-03-310.120.140.0216 
1997-03-17
1996-12-310.030.01-0.0266 
View All Earnings Estimates

Accelerate Diagnosti SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Accelerate Diagnosti prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Accelerate Diagnosti investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Accelerate Diagnosti specific information freely available to individual and institutional investors to make a timely investment decision.
28th of May 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
25th of May 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
13th of May 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Material Modifications to Rights of Security Holders
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of April 2021
Other Events
View
19th of March 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
23rd of February 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View
16th of February 2021
Unclassified Corporate Event
View

Accelerate Diagnosti Thematic Classifications

In addition to having Accelerate Diagnosti stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Measuring and Control IdeaMeasuring and Control
USA Equities from Measuring and Control industry as classified by Fama & French

Accelerate Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 568.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Accelerate Diagnosti's market, we take the total number of its shares issued and multiply it by Accelerate Diagnosti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Accelerate Profitablity

Accelerate Diagnosti's profitability indicators refer to fundamental financial ratios that showcase Accelerate Diagnosti's ability to generate income relative to its revenue or operating costs. If, let's say, Accelerate Diagnosti is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Accelerate Diagnosti's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Accelerate Diagnosti's profitability requires more research than a typical breakdown of Accelerate Diagnosti's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Investment(61.76) (66.64) 
Return on Average Assets(0.72) (0.74) 
Return on Average Equity 1.81  1.95 
Return on Invested Capital(0.30) (0.33) 
Return on Sales(5.61) (6.05) 

Management Efficiency

The entity has return on total asset (ROA) of (34.73) % which means that it has lost $34.73 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (837.84) %, meaning that it created substantial loss on money invested by shareholders. Accelerate Diagnosti management efficiency ratios could be used to measure how well accelerate diagnosti manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to rise to 1.95 in 2021, whereas Return on Investment is likely to drop (66.64)  in 2021. Accelerate Diagnosti Total Assets are fairly stable at the moment as compared to the past year. Accelerate Diagnosti reported Total Assets of 93.42 Million in 2020. Current Assets is likely to rise to about 87.4 M in 2021, whereas Assets Non Current are likely to drop slightly above 9.3 M in 2021.
Last ReportedProjected for 2021
Book Value per Share(1.12) (1.15) 
Enterprise Value over EBIT(9.00) (9.71) 
Enterprise Value over EBITDA(9.27) (10.00) 
Price to Book Value(6.88) (7.43) 
Tangible Assets Book Value per Share 1.67  1.89 
Enterprise Value552.8 M656.4 M
Tangible Asset Value93.4 M96.4 M

Technical Drivers

As of the 17th of June 2021, Accelerate Diagnosti shows the risk adjusted performance of 0.0173, and Mean Deviation of 2.37. Accelerate Diagnosti technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Accelerate Diagnosti, which can be compared to its rivals. Please confirm Accelerate Diagnosti standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Accelerate Diagnosti is priced correctly, providing market reflects its regular price of 8.61 per share. Given that Accelerate Diagnosti has jensen alpha of 0.0142, we suggest you to validate Accelerate Diagnosti's prevailing market performance to make sure the company can sustain itself at a future point.

Accelerate Diagnosti Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Accelerate Diagnosti more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Accelerate Diagnosti Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Accelerate Diagnosti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Accelerate Diagnosti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Accelerate Diagnosti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phillips Jack over three weeks ago via Macroaxis 
Acquisition by Phillips Jack of 206597 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over a month ago via Macroaxis 
Exercise or conversion by Phillips Jack of 79893 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over a month ago via Macroaxis 
Sale by Phillips Jack of 25064 shares of Accelerate Diagnosti
Phillips Jack over two months ago via Macroaxis 
Acquisition by Phillips Jack of 4340 shares of Accelerate Diagnosti subject to Rule 16b-3
Phillips Jack over three months ago via Macroaxis 
Acquisition by Phillips Jack of 79893 shares of Accelerate Diagnosti subject to Rule 16b-3
Matthew Strobeck over three months ago via Macroaxis 
Accelerate Diagnosti exotic insider transaction detected
Phillips Jack over three months ago via Macroaxis 
Acquisition by Phillips Jack of 4340 shares of Accelerate Diagnosti subject to Rule 16b-3
Humphries Romney over three months ago via Macroaxis 
Sale by Humphries Romney of 2000 shares of Accelerate Diagnosti
Jack Schuler over three months ago via Macroaxis 
Accelerate Diagnosti exotic insider transaction detected
Phillips Jack over three months ago via Macroaxis 
Exercise or conversion by Phillips Jack of 10000 shares of Accelerate Diagnosti subject to Rule 16b-3
Jack Schuler over three months ago via Macroaxis 
Accelerate Diagnosti exotic insider transaction detected
Steve Reichling over three months ago via Macroaxis 
Exercise or conversion by Steve Reichling of 25000 shares of Accelerate Diagnostics subject to Rule 16b-3

Accelerate Diagnosti Predictive Daily Indicators

Accelerate Diagnosti intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Accelerate Diagnosti stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Accelerate Diagnosti Forecast Models

Accelerate Diagnosti time-series forecasting models is one of many Accelerate Diagnosti's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Accelerate Diagnosti's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Accelerate Diagnosti Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Accelerate Diagnosti stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Accelerate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Accelerate Diagnosti. By using and applying Accelerate Stock analysis, traders can create a robust methodology for identifying Accelerate entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(42.00) (43.11) 
EBITDA Margin(5.34) (5.76) 
Gross Margin 0.40  0.56 
Profit Margin(7.00) (7.56) 
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona. Accelerate Diagnosti operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 224 people.

Current Accelerate Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Accelerate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Accelerate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.0Hold3Odds
Accelerate Diagnosti current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Accelerate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Accelerate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Accelerate Diagnosti, talking to its executives and customers, or listening to Accelerate conference calls.
Accelerate Analyst Advice Details

Accelerate Stock Analysis Indicators

Accelerate Diagnosti stock analysis indicators help investors evaluate how Accelerate Diagnosti stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Accelerate Diagnosti shares will generate the highest return on investment. By understating and applying Accelerate Diagnosti stock analysis, traders can identify Accelerate Diagnosti position entry and exit signals to maximize returns.
Quick Ratio10.02
Fifty Two Week Low6.60
Revenue Growth-10.40%
Shares Short Prior Month8.86M
Average Daily Volume Last 10 Day186.04k
Average Daily Volume In Three Month198.22k
Shares Percent Shares Out13.88%
Gross Margins39.94%
Short Percent Of Float23.99%
Forward Price Earnings-7.57
Float Shares27.74M
Fifty Two Week High19.11
Enterprise Value To Ebitda-8.43
Fifty Day Average7.52
Two Hundred Day Average8.80
Enterprise Value To Revenue45.52
Please continue to Trending Equities. Note that the Accelerate Diagnosti information on this page should be used as a complementary analysis to other Accelerate Diagnosti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Accelerate Diagnosti Stock analysis

When running Accelerate Diagnosti stock analysis, check to measure Accelerate Diagnosti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnosti is operating at the current time. Most of Accelerate Diagnosti's stock examination focuses on studying past and present price action to predict the probability of Accelerate Diagnosti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Accelerate Diagnosti's price. Additionally, you may evaluate how the addition of Accelerate Diagnosti to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
The market value of Accelerate Diagnosti is measured differently than its book value, which is the value of Accelerate that is recorded on the company's balance sheet. Investors also form their own opinion of Accelerate Diagnosti stock's value that differs from its market value or its book value, called intrinsic value, which is Accelerate Diagnosti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Accelerate Diagnosti's market value can be influenced by many factors that don't directly affect Accelerate Diagnosti underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Accelerate Diagnosti's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Accelerate Diagnosti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Accelerate Diagnosti's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.